Investors Buy Large Volume of Call Options on ARK Genomic Revolution ETF (BATS:ARKG)

ARK Genomic Revolution ETF (BATS:ARKG) saw unusually large options trading on Tuesday. Traders acquired 32,950 call options on the company. This is an increase of 125% compared to the average daily volume of 14,663 call options.

Institutional Trading of ARK Genomic Revolution ETF

A number of hedge funds have recently added to or reduced their stakes in ARKG. Two Sigma Investments LP lifted its position in ARK Genomic Revolution ETF by 626.8% during the 4th quarter. Two Sigma Investments LP now owns 961,500 shares of the company’s stock worth $22,639,000 after acquiring an additional 829,200 shares during the period. JPMorgan Chase & Co. lifted its position in ARK Genomic Revolution ETF by 31.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,955,279 shares of the company’s stock worth $75,655,000 after acquiring an additional 698,701 shares during the period. Tower Research Capital LLC TRC lifted its position in ARK Genomic Revolution ETF by 45,400.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 252,530 shares of the company’s stock worth $5,946,000 after acquiring an additional 251,975 shares during the period. Barclays PLC lifted its position in ARK Genomic Revolution ETF by 252.7% during the 3rd quarter. Barclays PLC now owns 285,108 shares of the company’s stock worth $7,299,000 after acquiring an additional 204,283 shares during the period. Finally, GTS Securities LLC raised its stake in shares of ARK Genomic Revolution ETF by 294.7% during the 4th quarter. GTS Securities LLC now owns 129,142 shares of the company’s stock worth $3,041,000 after buying an additional 195,486 shares in the last quarter.

ARK Genomic Revolution ETF Stock Up 24.9 %

ARK Genomic Revolution ETF stock opened at $29.49 on Wednesday. The stock’s fifty day moving average is $25.66 and its 200 day moving average is $25.29.

About ARK Genomic Revolution ETF

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.